DaVita Inc. Stock 12‑Month Price Target Cut to $227.67, Implies 18% Upside
DaVita Inc.'s average price target was reduced from $229 to $227.67 by 6 analysts, with a range of $180 to $270. This implies an 18% upside from the Oct. 29 closing price. The consensus rating remains 'Buy' among 11 analysts.
How this was made
The 30-second read
Why it matters
A small downward revision in price targets signals modest analyst concern but does not indicate a major catalyst.
Market read
The article provides a minor update to analyst expectations with limited trading impact.
What to watch
Potential upcoming earnings or regulatory developments could quickly change sentiment.
Background
DaVita Inc. is a leading provider of kidney dialysis services. Analyst consensus remains a Buy, but the average price target slipped slightly.
Ticker impact
Analysts lowered DaVita Inc.'s average 12‑month price target to $227.67, down from $229, implying ~18% upside from the recent close.
likely modest pressure as the market prices in the lower target
Target reduction is small and reflects a minor shift in analyst consensus rather than a material change in fundamentals.
Market effects
Minimal impact on the healthcare services sector; peers unlikely to be affected.
Limited to US markets where DaVita trades.
Low
Counterpoint
The target cut may be overly cautious; the stock could still rally if earnings beat expectations.
Key entities
- companyDaVita Inc.
US‑listed dialysis provider (NYSE:DVA).
